Научно-практическая конференция «Абсансная эпилепсия»

1. Авакян Г.Н., Белоусова Е.Д., Бурд С.Г. и др. Рекомендации экспертного совета Российской противоэпилептической лиги по применению оригинальных и воспроизведенных препаратов (дженериков) для лечения эпилепсии. Эпилепсия и пароксизмальные состояния 2011;3(1):17–9.

2. Гусяков Ф.И., Белоусова М.В., Морозова Е.А., Газизова Д.Г. Гетерогенность абсансных эпилепсий в детском возрасте. Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева 2021;55(3):32–44. DOI: 10.31363/2313-7053-2021-56-3-32-44

3. Ермоленко Н.А., Рудакова И.Г., Калмыкова Г.В. и др. Оценка эффективности и переносимости терапии больных эпилепсией: материалы заседания Совета экспертов неврологов-эпилептологов Центрального федерального округа. Москва, 10 декабря 2022 г. Клинический разбор в общей медицине 2023;4(6):13–9. DOI: 10.47407/kr2023.4.5.00266

4. Инструкция по применению лекарственного препарата для медицинского применения Сейзар. Instruction for use of the medicinal product Sazar. (In Russ.).

5. Карлов В.А. Абсанс. Журнал неврологии и психиатрии им. C.C. Корсакова 2005;105(3):55–60.

6. Карлов В.А. Эпилепсия у детей и взрослых женщин и мужчин: руководство для врачей. М.: Бином, 2019. 896 c.

7. Карлов В.А., Овнатанов Б.С. Медиобазальные эпилептические очаги и абсансная активность на ЭЭГ. Журнал невропатологии и психиатрии им. С.С. Корсакова 1986;87(6):805–12.

8. Клинические рекомендации. Эпилепсия и эпилептический статус у взрослых и детей. 2022. Доступно по: https://cr.minzdrav.gov.ru/recomend/741_1

9. Клинические рекомендации. Эпилепсия и эпилептический статус у взрослых и детей. 2023. Доступно по: https://npcpn.ru/doc/2021/kr-epilepsiya.pdf

10. Кулиш Е.А., Котов А.С., Мухина Е.В. и др. Синдром дефицита транспортера глюкозы I типа: клинический случай. Русский журнал детской неврологии 2019;14(2):23–8. DOI: 10.17650/2073-8803-2019-14-2-23-28

11. Лечение синдрома дефицита GLUT1. Клинические рекомендации Минздрава России. Доступно по: https://diseases.medelement.com/disease/синдром-дефицитаglut1-кп-рф-2024/18123.

12. Лукьянова Е.Г., Пырьева Е.А., Сорвачева Т.Н. и др. Кетогенная диета в лечении детей с фармакорезистентной эпилепсией. Отечественный опыт и перспективы. Российский неврологический журнал 2021;26(5):52–60. DOI: 10.30629/2658-7947-2021-26-5-52-60

13. Мухин К.Ю., Миронов М.Б., Пылаева О.А. Эпилепсия с миоклонически-астатическими приступами (синдром Дозе). Русский журнал детской неврологии 2013;8(1):25–38. DOI: 10.17650/2073-8803-2013-8-1-25-38

14. Мухин К.Ю., Петрухин А.С. Эпилептические синдромы. Клинико-электроэнцефалографическая диагностика и терапия. В кн.: Эпилептические синдромы. Диагностика и терапия. Под ред. К.Ю. Мухина, Л.Ю. Глуховой, М.Ю. Бобыловой и др. 6-е изд. М.: Русский печатный двор, 2023. С. 146–323.

15. Мухин К.Ю., Петрухин А.С., Калинина Л.В. и др. Типичные абсансы: клиническая систематизация и терапия. Вестник практической неврологии 1995;1(1):30–40.

16. Мухин К.Ю., Пылаева О.А., Бобылова М.Ю., Фрейдкова Н.В. Ламотриджин (Сейзар) в лечении эпилепсии: результаты 4-летнего применения препарата в Объединении медицинских учреждений по диагностике, лечению и реабилитации заболеваний нервной системы и эпилепсии им. Святителя Луки. Русский журнал детской неврологии 2022;17(3):8–36. DOI: 10.17650/2073-8803-2022-17-3-8-36

17. Новые данные о безопасности популярных противосудорожных препаратов. Катренстиль: онлайн-журнал для фармацевтов и медицинских работников 2024;244. Доступно по: https://www.katrenstyle.ru/news/novye_dannye_o_bezopasnosti_populyarnykh_protivosudorozhnykh_preparatov.

18. Пылаева О.А., Мухин К.Ю. Эффективность и переносимость Сейзара (ламотриджин) в лечении эпилепсии (опыт Института детской неврологии и эпилепсии им. Свт. Луки). Русский журнал детской неврологии 2020;15(2):17–41. DOI: 10.17650/2073-8803-2020-15-2-17-41

19. Рудакова И.Г. Лечение эпилепсии в режиме взаимозамен и качество контроля эпилепсии – актуальные вопросы клинической практики. Фокус – ламотриджин. Вестник эпилептологии 2023;1:19–29.

20. Сейзар. Регистр лекарственных средств России. Доступно по: https://www.rlsnet.ru/drugs/seizar-36856.

21. Синкин М.В., Кваскова Н.Е., Брутян А.Г. и др. Русскоязычный словарь терминов, используемых в клинической электроэнцефалографии. Нервные болезни 2021;1:83–8. DOI: 10.24412/2226- 0757-2021-12312

22. Усачева Е.Л., Айвазян С.О., Сорвачева Т.Н. и др. Применение кетогенной диеты в лечении фармакорезистентных эпилепсий. Журнал неврологии и психиатрии им. С.С. Корсакова 2004;7:29–34.

23. Эпилепсия. Атлас электроклинической диагностики и терапии. T. 1. Под ред. К.Ю. Мухина, Л.Ю. Глуховой, А.А. Холина. М.: Русский Печатный Двор, 2023. 912 с.

24. Эпилепсия. Атлас электроклинической диагностики и терапии. Т. 2. Под ред. К.Ю. Мухина, Л.Ю. Глуховой, А.А. Холина. М.: Русский Печатный Двор, 2024. 884 с.

25. Aldenkamp A.P., Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2001;2(2):85–91. DOI: 10.1006/ebeh.2001.0168

26. Bartolomei F., Genton P., Dravet Ch. et al. Comparative clinical and EEG study of Juvenile and childhood absence epilepsies. Epilepsia 1995;36(S3):S75–6.

27. Ben-Zeev B., Watemberg N., Lerman P. et al. Sulthiame in childhood epilepsy. Pediatr Int 2004;46(5):521–4. DOI: 10.1111/j.1442-200x.2004.01954.x

28. Berg M., Welty T.E., Gidal B.E. Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial. JAMA Neurol 2017;74(8):919–26. DOI: 10.1001/jamaneurol.2017.0497

29. Brigo F., Igwe S.C. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2017;2(2):CD003032. DOI: 10.1002/14651858.CD003032.pub3

30. Calmeil L.F. De 1’ pilepsie étudi e saus le rapport de son si ge et de son influence sur la production de ali nation mentale; th se pr sent e et soutenue la Facult de M decine de Paris. Paris, 1824. (In French).

31. Carter E.G., Armour E.A., Pagano L.M., Reddy S.B. Epilepsy with myoclonic absences: a case series highlighting clinical heterogeneity and surgical management. Epileptic Disord 2022;24(3):541–7. DOI: 10.1684/epd.2022.1420

32. Cerulli Irelli E., Cocchi E., Morano A. et al. Women with Epilepsy Treatment Options and Research (WETOR) Study Group. Levetiracetam vs lamotrigine as first-line antiseizure medication in female patients with idiopathic generalized epilepsy. JAMA Neurol 2023;80(11):1174–81. DOI: 10.1001/jamaneurol.2023.3400

33. Kuo C.C. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol Pharmacol 1998;54:712–21.

34. Cnaan A., Shinnar S., Arya R. et al. Childhood Absence Epilepsy Study Group. Second monotherapy in childhood absence epilepsy. Neurology 2017;88(2):182–90. DOI: 10.1212/WNL.0000000000003480

35. Conrad E.C., Chugh N., Ganguly T.M. et al. Using generalized polyspike train to predict drug-resistant idiopathic generalized epilepsy. J Clin Neurophysiol 2022;39(6):459–65. DOI: 10.1097/WNP.0000000000000803

36. Coppola G., Licciardi F., Sciscio N. et al. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004;26(1):26–9. DOI: 10.1016/s0387-7604(03)00090-1

37. Coppola G., Veggiotti P., Cusmai R. et al. The ketogenic diet in children, adolescents and young adults with refractory epilepsy: an Italian multicentric experience. Epilepsy Res 2002;48(3):221–7. DOI: 10.1016/s0920-1211(01)00315-1

38. Crunelli V., Leresch N., Cope D.W. GABA-A receptor function in typical absence seizures. In: Jasper’s basic mechanisms of the epilepsies. Eds.: J.L. Noebels, M. Avoli, M.A. Rogawski. 4th edn. Bethesda: National Center for Biotechnology Information, 2012.

39. Crunelli V., Leresche N. Childhood absence epilepsy: genes, channels, neurons and networks. Nat Rev Neurosci 2002;3(5):371–82. DOI: 10.1038/nrn811

40. Temkin O. The Falling sickness. John Hopkins University Press, 1994.

41. Dlugos D., Shinnar S., Cnaan A. et al. Childhood Absence Epilepsy Study Team. Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcome. Neurology 2013;81(2):150–6. DOI: 10.1212/WNL.0b013e31829a3373

42. Doose H. Myoclonic astatic epilepsy of early childhood. In: Epileptic syndromes in infancy, childhood and adolescence. Eds.: J. Roger, M. Bureau, Ch. Dravet et al. London, 1992. Pp. 103–114.

43. Duchowny M., Pellock J.M., Graf W.D. et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology 1999;53(8):1724–31. DOI: 10.1212/wnl.53.8.1724

44. Dusanter C., Houot M., Mere M. et al. Cognitive effect of antiseizure medications in medial temporal lobe epilepsy. Eur J Neurol 2023;30(12):3692–702. DOI: 10.1111/ene.16050

45. Ferner R.E., Panayiotopoulos C.P. “Phantom” typical absences, absence status and experiential phenomena. Seizure 1993;2:253–6. DOI: 10.1016/s1059-1311(05)80135-9

46. Fisher R.S., Cross J.H., D’Souza C. et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 2017;58(4):531–42. DOI: 10.1111/epi.13671

47. Fonseca Wald E.L.A., Klinkenberg S., Voncken T.P.C. et al. Cognitive development in absence epilepsy during long-term followup. Child Neuropsychol 2019;25(8):1003–21. DOI: 10.1080/09297049.2019.1614156

48. Frank L.M., Enlow T., Holmes G.L. et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40(7):973–9. DOI: 10.1111/j.1528-1157.1999.tb00805.x

49. Garnett W.R., St Louis E.K., Henry T.R., Bramley T. Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. Curr Neuropharmacol 2009;7(2):83–95. DOI: 10.2174/157015909788848884

50. Gibbs F.A., Davis H., Lennox W.G. The electroencephalogram in epilepsy and in conditions of impaired consciousness. Arch Neurol Psych 1935;34(6):1135–48. DOI: 10.1001/archneurpsyc.1935.02250240002001

51. Glauser T.A., Holland K., O’Brien V.P. et al. Childhood Absence Epilepsy Study Group. Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Ann Neurol 2017;81(3):444–53. DOI: 10.1002/ana.24886

52. Glauser T.A., Cnaan A., Shinnar S. et al. Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 2013;54(1):141–55. DOI: 10.1111/epi.12028

53. Gossman W., Albuja A.C., Murphy P.B. Absence Seizure. StatPearls Publishing, 2019.

54. Grunze H., Greene R.W., Moller H.J. et al. Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current. Brain Res 1998;791:330–4. DOI: 10.1016/s0006-8993(98)00180-2

55. Grunze H., Von Wegerer J., Greene R.W., Walden J. Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 1998;38:131–8. DOI: 10.1159/000026528

56. Guerrini R., Mari F., Auvin S., Dravet C. Myoclonic epilepsies in infancy and early childhood. In: Epileptic Syndromes in infancy, childhood and adolescence. Eds.: M. Bureau, P. Genton, A.V. Delgado-Escueta et al. 6th edn. Paris: John Libbey Eurotext Ltd., 2019. Pp.173–188.

57. Guilhoto L.M. Absence epilepsy: continuum of clinical presentation and epigenetics? Seizure 2017;44:53–7. DOI: 10.1016/j.seizure.2016.11.031

58. Han M.J., Kim S.J. Effects of antiepileptic drugs on language abilities in benign epilepsy of childhood with centrotemporal spikes. J Clin Neurol 2018;14(4):523–9. DOI: 10.3988/jcn.2018.14.4.523

59. Hansen C.C., Ljung H., Brodtkorb E., Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. Behav Neurol 2018;2018:2064027. DOI: 10.1155/2018/2064027

60. Holmes G.L., Fisher R. Childhood absence epilepsy. 2013. Available at: https://www.epilepsy.com/what-is-epilepsy/syndromes/childhood-absence-epilepsy.

61. Holmes G.L., Frank L.M., Sheth R.D. et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res 2008;82(2–3):124–32. DOI: 10.1016/j.eplepsyres.2008.07.016

62. Holtkamp M., Theodore W.H. Generic antiepileptic drugs-safe or harmful in patients with epilepsy? Epilepsia 2018;59(7):1273–81. DOI: 10.1111/epi.14439

63. Hwang H., Kim H., Kim S.H. et al. Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. Brain Dev 2012;34(5):344–8. DOI: 10.1016/j.braindev.2011.08.007

64. IJff D.M., van Veenendaal T.M., Debeij-van Hall M.H. et al. The cognitive profile of ethosuximide in children. Paediatr Drugs 2016;18(5):379–85. DOI: 10.1007/s40272-016-0187-z

65. Information on the risks of Valproate use in girls (of any age) and women of childbearing potential (Epilim, Depakote, Convulex, Episenta, Epival, Kentlim, Orlept, Sodium Valproate, Syonell, Valpal, Belvo & Dyzantil). Medicines and Healthcare Products Regulatory Agency. 2020. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950802/107995_Valproate_HCP_Booklet_DR15_v07_DS_07-01-2021.pdf.

66. Ivanova N., Peycheva V., Kamenarova K. et al. Three novel SLC2A1 mutations in Bulgarian patients with different forms of genetic generalized epilepsy reflecting the clinical and genetic diversity of GLUT1-deficiency syndrome. Seizure 2018;54:41–4. DOI: 10.1016/j.seizure.2017.11.014

67. Jain P. Absence seizures in children: usual and the unusual. Indian J Pediatr 2020;87(12):1047–56. DOI: 10.1007/s12098-020-03423-8

68. Jasper H.H., Droogleever-Fortuyn J. Experimental studies on the functional anatomy of petit mal epilepsy. Assoc Res Nerv Ment Dis 1947;26:272–98.

69. Kang J.Q., Macdonald R.L. Molecular pathogenic basis for GABRG2 mutations associated with a spectrum of epilepsy syndromes, from generalized absence epilepsy to Dravet syndrome. JAMA Neurol 2016;73(8):1009–16. DOI: 10.1001/jamaneurol.2016.0449

70. Kessler S.K., McGinnis E. A practical guide to treatment of childhood absence epilepsy. Paediatr Drugs 2019;21(1):15–24. DOI: 10.1007/s40272-019-00325-x

71. Kossoff E.H., Zupec-Kania B.A., Auvin S. et al. Charlie Foundation; Matthew’s Friends; Practice Committee of the Child Neurology Society. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open 2018;3(2):175–92. DOI: 10.1002/epi4.12225

72. Koutroumanidis M. The role of EEG in the diagnosis and classification of epilepsy syndromes. John Libbey Eurotext, 2017. P. 200.

73. Koutroumanidis M., Arzimanoglou A., Caraballo R. et al. The role of EEG in the diagnosis and classification of the epilepsy syndromes: a tool for clinical practice by the ILAE Neurophysiology Task Force (Part 1). Epileptic Disord 2017;19(3):233–98. DOI: 10.1684/epd.2017.0935

74. Koutroumanidis M., Aggelakis K., Panayiotopoulos C.P. Idiopathic epilepsy with generalized tonic-clonic seizures only versus idiopathic epilepsy with phantom absences and generalized tonic-clonic seizures: one or two syndromes? Epilepsia 2008;49:2050–62. DOI: 10.1111/j.1528-1167.2008.01702.x

75. Larsen J., Johannesen K.M., Ek J. et al. The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. Epilepsia 2015;56(12):e203–8. DOI: 10.1111/epi.13222

76. Liu Y., Bao X., Wang D. et al. Allelic variations of GLUT1 deficiency syndrome: the Chinese experience. Pediatr Neurol

77. ;47(1):30–4. DOI: 10.1016/j.pediatrneurol.2012.04.010

78. Matricardi S., Verrotti A., Chiarelli F. et al. Current advances in childhood absence epilepsy. Pediatr Neurol 2014;50(3):205–12. DOI: 10.1016/j.pediatrneurol.2013.10.009

79. Mattozzi S., Cerminara C., Sotgiu M.A. et al. Occurrence of hyperventilation-induced high amplitude rhythmic slowing with altered awareness after successful treatment of typical absence seizures and a network hypothesis. Clin Neurophysiol Pract 2021;6:185–8. DOI: 10.1016/j.cnp.2021.03.009

80. Medina M., Genton P., Bureau M. et al. Absence epilepsies. In: Epileptic syndromes in infancy, childhood and adolescence. Eds.: M. Bureau, P. Genton, C. Dravet et al. 6th ed. Paris: John Libbey Eurotext Ltd., 2019. Pp. 285–320.

81. Mignot K., von St lpnagel C., Nava C. et al. Genetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy [published correction appears in J Med Genet 2016;53(10):720]. J Med Genet 2016;53(8):511–22. DOI: 10.1136/jmedgenet-2015-103451

82. Moavero R., Pisani L.R., Pisani F., Curatolo P. Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf 2018;17(10):1015–28. DOI: 10.1080/14740338.2018.1518427

83. Mori T., Sakamoto M., Tayama T. et al. A case of epilepsy with myoclonic atonic seizures caused by SLC6A1 gene mutation due to balanced chromosomal translocation. Brain Dev 2023;45(7):395–400. DOI: 10.1016/j.braindev.2023.03.001

84. Mostacci B., Ranzato F., Giuliano L. et al. Alternatives to valproate in girls and women of childbearing potential with idiopathic generalized epilepsies: state of the art and guidance for the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against Epilepsy (LICE). Seizure 2021;85:26–38. DOI: 10.1016/j.seizure.2020.12.005

85. Mukhin K.Yu., Medvedev M.I., Petrukhin A.S. Epilepsy with myoclonic-astatic seizures: diagnostic criterion and treatment. Brain Dev 1998;20(6):481.

86. Myers K.A. Genetic epilepsy syndromes. Continuum (Minneap Minn) 2022;28(2):339–62. DOI: 10.1212/CON.0000000000001077

87. Epilepsies in children, young people and adults. National Institute for Health and Care Excellence guideline. 2022. Available at: https://www.nice.org.uk/guidance/ng217/.

88. Nickels K., Kossoff E.H., Eschbach K., Joshi C. Epilepsy with myoclonic-atonic seizures (Doose syndrome): clarification of diagnosis and treatment options through a large retrospective multicenter cohort. Epilepsia 2021;62(1):120–7. DOI: 10.1111/epi.16752

89. Panayiotopoulos C.P. Idiopathic generalized epilepsies. Springer, 2012. Pp. 41–44.

90. Panayiotopoulos C.P. A clinical guide to epileptic syndromes and their treatment. 2nd edn. Springer, 2010. Pp. 45–49; 325–335.

91. Panayiotopoulos C.P. Syndromes of idiopathic generalized epilepsies not recognized by the International League against epilepsy. Epilepsia 2005;46(Suppl 9):57–66. DOI: 10.1111/j.1528-1167.2005.00314.x

92. Panayiotopoulos C.P., Ferrie C.D., Koutroumanidis M. et al. Idiopathic generalised epilepsy with phantom absences and absence status in a child. Epileptic Disord 2001;3(2):63–6.

93. Panayiotopoulos C.P., Koutroumanidis M., Giannakodimos S., Agathonikou A. Idiopathic generalised epilepsy in adults manifested by phantom absences, generalised tonic-clonic seizures, and frequent absence status. J Neurol Neurosurg Psychiatry 1997;63:622–7. DOI: 10.1136/jnnp.63.5.622

94. Panayiotopoulos С.P. Principles of therapy in the epilepsies. In: Clinical guide to epileptic syndromes and their treatment. Springer, 2007. Pp. 155–184.

95. Pearl P.L. Epilepsy syndromes in childhood. Continuum (Minneap Minn) 2018;24(1, Child Neurology):186–209. DOI: 10.1212/CON.0000000000000568

96. Pellock J., Montouris G.D., Ramsay R.E. New developments in the treatment of epilepsy. CNS Spectrums 2000;5(S2):1–8. DOI: 10.1017/S1092852900023579

97. Peltola M.E., Leitinger M., Halford J.J. et al. Routine and sleep EEG: minimum recording standards of the International Federation of Clinical Neurophysiology and the International League Against Epilepsy. Epilepsia 2023;64(3):602–18. DOI: 10.1111/epi.17448

98. Porwal M.H., Razzak A.N., Kumar V. et al. An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database. Epilepsy Res 2024;203:107382. DOI: 10.1016/j.eplepsyres.2024.107382

99. Posner E.B., Mohamed K., Marson A.G. A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure 2005;14(2):117–22. DOI: 10.1016/j.seizure.2004.12.003

100. Ramm-Pettersen A., Nakken K.O., Haavardsholm K.C., Selmer K.K. GLUT1-deficiency syndrome: report of a four-generation Norwegian family with a mild phenotype. Epilepsy Behav 2017;70(Pt A):1–4. DOI: 10.1016/j.yebeh.2017.02.016

101. Reed L., Ciliberto M., Fong S.L. et al. Efficacy of felbamate in a cohort of patients with epilepsy with myoclonic atonic seizures (EMAtS). Epilepsy Res 2024;201:107314. DOI: 10.1016/j.eplepsyres.2024.107314

102. Rinaldi V.E., Di Cara G., Mencaroni E., Verrotti A. Therapeutic options for childhood absence epilepsy. Pediatr Rep 2021;13(4):658–67. DOI: 10.3390/pediatric13040078

103. Sadleir L.G., Scheffer I.E., Smith S. et al. EEG features of absence seizures in idiopathic generalized epilepsy: impact of syndrome, age, and state. Epilepsia 2009;50(6):1572–8. DOI: 10.1111/j.1528-1167.2008.02001.x

104. Sadleir L.G., Farrell K., Smith S. et al. Electroclinical features of absence seizures in childhood absence epilepsy. Neurology 2006;67(3):413–8. DOI: 10.1212/01.wnl.0000228257.60184.82

105. Scheffer I.E., Berkovic S., Capovilla G. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512–21. DOI: 10.1111/epi.13709

106. Seneviratne U., Cook M.J., D’Souza W.J. Electroencephalography in the diagnosis of genetic generalized epilepsy syndromes. Front Neurol 2017;8:499. DOI: 10.3389/fneur.2017.00499

107. Smith D., Baker G., Davies G. et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34(2):312–22. DOI: 10.1111/j.1528-1157.1993.tb02417.x

108. Smith K.M., Wirrell E.C., Andrade D.M. et al. Management of epilepsy with eyelid myoclonia: results of an international expert consensus panel. Epilepsia 2023;64(9):2342–50. DOI: 10.1111/epi.17682

109. Smith K.M., Wirrell E.C., Andrade D.M. et al. Clinical presentation and evaluation of epilepsy with eyelid myoclonia: results of an international expert consensus panel. Epilepsia 2023;64(9):2330–41. DOI: 10.1111/epi.17683

110. Smith K.M., Wirrell E.C., Andrade D.M. et al. A comprehensive narrative review of epilepsy with eyelid myoclonia. Epilepsy Res 2023;193:107147. DOI: 10.1016/j.eplepsyres.2023.107147

111. Specchio N., Wirrell E.C., Scheffer I.E. et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1398–442. DOI: 10.1111/epi.17241

112. St Louis E.K., Gidal B.E., Henry T.R. et al. Conversions between monotherapies in epilepsy: expert consensus. Epilepsy Behav 2007;11(2):222–34. DOI: 10.1016/j.yebeh.2007.04.007

113. Stafstrom C.E. Dietary approaches to epilepsy treatment: old and new options on the menu. Epilepsy Curr 2004;4(6):215–22. DOI: 10.1111/j.1535-7597.2004. 46001.x

114. Strzelczyk A., Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs 2022;36(10):1079–111.

115. Tassinari C.A., Lyagoubi S., Santos V. et al. Study on spike and wave discharges in man. II. Clinical and electroencephalographic aspects of myoclonic absences. Rev Neurol (Paris) 1969;121(3):379–83. (In French).

116. Tissot S.A. Trait de l’ pilepsie. Faisant le tome troisi me du Trait des nerfs & de leurs maladies. Paris: Didot Le Jeune, 1770. (In French).

117. Tomson T., Battino D., Bromley R. et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord 2019;21(6):497–517. DOI: 10.1684/epd.2019.1105

118. Topiramate side effects (Topamax) guide. Most common to severe side effects of topiramate. Side effects topiramate prescription can cause. Topiramate side effects 25 mg to the highest dosage.Topiramate side effect treatment. Ed. by Y. Francese. 2023. Available at: https://welevelupnj.com/treatment/topiramate-sideeffects/.

119. Trevathan E., Kerls S.P., Hammer A.E. et al. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Pediatrics 2006;118(2):e371–8. DOI: 10.1542/peds.2006-0148

120. Typical absence seizure. Clinical overview. Available at: https://www.epilepsydiagnosis.org/seizure/absence-typicaloverview.html.

121. Typical Absenсe Seizures. International League Against Epilepsy. Available at: https://www.epilepsydiagnosis.org/seizure/absencetypicalrelatedsyndromes.html.

122. Typical absence seizure. Related syndromes. Available at: https://www.epilepsydiagnosis.org/seizure/absencetypicalrelatedsyndromes.html.

123. Unterberger I., Trinka E., Kaplan P.W. et al. Generalized nonmotor (absence) seizures – what do absence, generalized, and nonmotor mean? Epilepsia 2018;59(3):523–9. DOI: 10.1111/epi.13996

124. Beniczky S., Trinka E., Abdulla F. Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Available at: https://www.ilae.org/files/dmfile/updated-sz-classification2.pdf.

125. Valproate use in men: as a precaution, men and their partners should use effective contraception. 2024. Available at: https://www.gov.uk/drug-safety-update/valproate-use-in-men-as-a-precaution-menand-their-partners-should-use-effectivecontraception.

126. Van der Louw E., Trimmel-Schwahofer P., Devlin A. et al. Human milk and breastfeeding during ketogenic diet therapy in infants with epilepsy: clinical practice guideline. Dev Med Child Neurol 2024;66(10):1276–88. DOI: 10.1111/dmcn.15928

127. Varesio C., Provenzi L., Donetti Dontin S. et al. Pathways to quality of life in adolescents with genetic generalized epilepsy: the role of seizure features and affective symptoms. Epilepsy Behav 2020;109:107115. DOI: 10.1016/j.yebeh.2020.107115

128. Videira G., Raimundo R., Chor o R. Epilepsy with myoclonic absences: a case series. Seizure 2023;106:162–3. DOI: 10.1016/j.seizure.2023.02.017

129. Vining E.P., Freeman J.M., Ballaban-Gil K. et al. A multicenter study of the efficacy of the ketogenic diet. Arch Neurol 1998;55(11):1433–7. DOI: 10.1001/archneur.55.11.1433

130. Williams D. A study of thalamic and cortical rhythms in petit mal. Brain 1953;76(1):50–69. DOI: 10.1093/brain/76.1.50

131. Wirrell E.С., Nabbout R., Scheffer I. et al. Methodology for classification and definition of epilepsy syndromes: report of the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1333–48. DOI: 10.1111/epi.17237

132. Wirrell E., Sirven J.I., Fisher R. Juvenile myoclonic epilepsy. 2019. Available at: https://www.epilepsy.com/what-is-epilepsy/syndromes/juvenile-myoclonic-epilepsy.

133. Xiong Z.G., Chu X.P., MacDonald J.F. Effect of lamotrigine on the Ca2+-sensing cation current in cultured hippocampal neurons. J Neurophysiol 2001;86:2520–6. DOI: 10.1152/jn.2001.86.5.2520